logo
Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy

Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy

Biocon Ltd on Monday said its arm Biocon Biologics Ltd has received marketing authorisations from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for Vevzuo and Evfraxy, biosimilars of Denosumab used in the treatment of bone-related diseases.
Vevzuo is authorised for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, Biocon said in a regulatory filing.
It is also authorised for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
On the other hand, Evfraxy is authorised for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, the company said.
In postmenopausal women, this significantly reduces the risk of vertebral, non-vertebral, and hip fractures, it added.
Evfraxy is also authorised for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Biocon Biologics was recently granted marketing authorisation for Denosumab biosimilars by the European Commission (EC), allowing their commercialisation in all European Union (EU) member states and the European Economic Area (EEA), the company said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biocon Biologics gets USFDA nod for diabetes medication
Biocon Biologics gets USFDA nod for diabetes medication

Economic Times

time30-07-2025

  • Economic Times

Biocon Biologics gets USFDA nod for diabetes medication

Agencies Representative image. New Delhi: Biocon Biologics on Wednesday said it has received approval from the US health regulator to market a diabetes treatment medication. The company, a unit of Biocon Ltd, has received approval from the US Food and Drug Administration (USFDA) for Kirsty as the first and only interchangeable biosimilar to NovoLog (Insulin Aspart). Kirsty is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. The medication will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use, Biocon said in a statement. The approval expands Biocon Biologics' biosimilar insulin portfolio, which also includes the interchangeable biosimilar, Semglee (Insulin Glargine-yfgn Injection). An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP). Kirsty has been available in Europe and Canada since 2022. As per the company, there are 38.4 million people with diabetes in the US, around 11.6 per cent of the total population, with nearly a quarter of them being undiagnosed. An additional 97.6 million Americans have been identified as prediabetic, it added. According to IQVIA, sales of Insulin Aspart in the US stood around USD 1.9 billion in 2024. Shares of Biocon were trading 1.44 per cent up at Rs 395.80 apiece on the BSE.

Biocon Biologics receives UK MHRA marketing authorisations for Vevzuo and Evfraxy
Biocon Biologics receives UK MHRA marketing authorisations for Vevzuo and Evfraxy

Business Standard

time07-07-2025

  • Business Standard

Biocon Biologics receives UK MHRA marketing authorisations for Vevzuo and Evfraxy

Biocon Biologics announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisations in the United Kingdom (UK) for Vevzuo and Evfraxy, biosimilars of Denosumab. Vevzuo is authorized for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone. Vevzuo is also authorized for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Evfraxy is authorized for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women this significantly reduces the risk of vertebral, non-vertebral, and hip fractures. Furthermore, Evfraxy is authorized for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, this significantly reduces the risk of vertebral fractures. Evfraxy is also authorized for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. Clinical data showed that both Denosumab biosimilars have comparable safety and efficacy to the reference product. In Europe, the European Commission (EC) recently granted marketing authorisation for Biocon Biologics Denosumab biosimilars, allowing their commercialization in all European Union (EU) member states and the European Economic Area (EEA).

Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy
Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy

Business Standard

time07-07-2025

  • Business Standard

Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy

Biocon Ltd on Monday said its arm Biocon Biologics Ltd has received marketing authorisations from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for Vevzuo and Evfraxy, biosimilars of Denosumab used in the treatment of bone-related diseases. Vevzuo is authorised for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, Biocon said in a regulatory filing. It is also authorised for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. On the other hand, Evfraxy is authorised for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, the company said. In postmenopausal women, this significantly reduces the risk of vertebral, non-vertebral, and hip fractures, it added. Evfraxy is also authorised for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Biocon Biologics was recently granted marketing authorisation for Denosumab biosimilars by the European Commission (EC), allowing their commercialisation in all European Union (EU) member states and the European Economic Area (EEA), the company said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store